Related Experiment Video
Updated: Mar 11, 2026
06:07
Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
Published on: June 23, 2023
2.4K
Muscarinic receptor binding changes in postmortem Parkinson's disease
Caitlin McOmish1,2, Geoff Pavey3, Catriona McLean4
1The Florey Institute for Neuroscience and Mental Health, Melbourne, VIC, Australia. caitlin.mcomish@gmail.com.
Journal of Neural Transmission (Vienna, Austria : 1996)
|November 23, 2016
Summary
This study reveals increased M3 muscarinic receptors in Parkinson's disease (PD) brain regions and M2/M4 receptors in the cortex. These findings highlight cholinergic system dysfunction in PD aetiology.
Area of Science:
- Neuroscience
- Neurochemistry
- Pathology
Background:
- Parkinson's disease (PD) involves neurodegeneration, impacting dopaminergic and increasingly, cholinergic systems.
- While overall cholinergic changes are noted in PD, specific acetylcholine receptor contributions remain unclear.
- Understanding these receptor alterations is crucial for elucidating PD's complex pathology.
Purpose of the Study:
- To investigate the role of specific muscarinic acetylcholine receptors in Parkinson's disease.
- To quantify M1, M3, and M2/M4 receptor binding in postmortem brain tissues from PD patients and controls.
Main Methods:
- Utilized in situ radioligand binding assays with [3H]pirenzepine, [3H]4DAMP, and [3H]AF-DX 384.
- Analyzed postmortem tissues from Brodmann's areas 6, 9, 46, and caudate putamen.
- Compared receptor binding between Parkinson's disease and matched control groups.
Main Results:
- No significant difference in M1 receptor binding ([3H]pirenzepine) between PD and controls.
- Increased M3 receptor binding ([3H]4DAMP) observed in the caudate putamen and Brodmann's area 9 in PD.
- Elevated M2/M4 receptor binding ([3H]AF-DX 384) found in Brodmann's area 9 of PD patients.
Conclusions:
- Demonstrates selective upregulation of M3 muscarinic receptors in cortical and subcortical areas in PD.
- Indicates increased M2/M4 receptors in a specific cortical region (BA9) in Parkinson's disease.
- These findings support a significant role for cholinergic system dysfunction in the pathophysiology of Parkinson's disease.
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:25Cholinergic Receptors: Muscarinic
5.7K
The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine.
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
5.7K
01:15Parkinson's Disease: Overview
2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
01:37Neural Regulation
44.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
44.0K
01:22Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
2.4K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
2.4K
00:59Direct-Acting Cholinergic Agonists: Pharmacological Actions
2.5K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
2.5K